National differences in reporting ‘pneumonia’ and ‘pneumonia interstitial’: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions-Reference-Cited by-同舟云学术

National differences in reporting ‘pneumonia’ and ‘pneumonia interstitial’: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions

Published:2005-11 Issue:11 Volume:14 Page:775-787
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidem. Drug Safe.

Author:

Koo Linda C.,Clark John A.,Quesenberry Charles P.,Higenbottam Tim,Nyberg Fredrik,Wolf Michael K.,Steinberg Mark H.,Forsythe Beverley H.

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference25 articles.

1. FDA, CDER. Questions and answers on Iressa (gefitinib). May 5, 2003. http://www.fda.gov/cder/drug/infopage/iressa/iressaQ&A.htm

2. The safety of AstraZeneca's IRESSA: the US oncology view. http://www.trends-in-medicine.com, Nov. 2002; 1-4.

3. Japan deaths spark concerns over arthritis drug

4. WHO Uppsala Monitoring Centre. Viewpoint, Part I, Watching for Safer Medicines. WHO-UMC: Uppsala, Sweden, 2002.

5. World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. WHO: Geneva, 2002.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer;British Journal of Clinical Pharmacology;2024-08-19

2. Incidence and Clinical Characteristics of Drug-Induced Lung Disease Among Chemotherapy Recipients;Cureus;2024-06-28

3. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11

4. Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study;Respiratory Investigation;2024-03

5. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021;Therapeutic Advances in Drug Safety;2024-01